Should every patient with MDS get iron chelation – probably yes.

Main Article Content

Kanjaksha Ghosh
Emanuele Angelucci
Federica Pilo
Kinjalka Ghosh
(*) Corresponding Author:



Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Kanjaksha Ghosh, Director Surat Raktadan Kendra & Research Centre Udhna Khatodara Urban health Centre Udhna Magdalla road Surat 395002

Surat Raktadan Kendra & Research Centre
Udhna Khatodara Urban health Centre
Udhna Magdalla road
Surat 395002


1. Angelucci E, Urru SA, Pilo F, Piperno A. Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis. 2017 Mar 1;9:e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017.
2.Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br. Jr. Haematol. 2017.177:741-750.
3. Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry .Leuk Res. 2012;36:1067-70.
4. Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N.Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016 ;35:3577-86.
5. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006 ;91:1588-90.
6.Fibach E, Rachmilewitz EASelective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS. Leuk. Res. 2012;36:962-3.
7. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF,Rachmilewitz EA, Hebbel RPDeferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood.199586:2008-13.
8.Cazzola M, Della Porta MG, Malcovati L.The genetic basis of myelodysplasia and its clinical relevance. Blood.2013 ;122:4021-34.
9.Prá D, Franke SI, Henriques JA, Fenech M.Iron and genome stability: an update. Mut. Res. 2012;733:92-9.
10.Gupta M, Madkaikar M, Rao VB, Mishra A, Govindaraj P, Thangaraj K, Ghosh K Mitochondrial DNA variations in myelodysplastic syndrome. Annals . Hematol.2013;92:871-6.
11.Reddy PL, Shetty VT, Dutt D, York A, Dar S, Mundle SD, Allampallam K, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh M, Suleman S, Kamal SY, Raza A(2002).Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br. Jour. Haematol.2002;116:564-75.
12.Nairz M, Schroll A, Demetz E, Tanncevski I, Theurl I, Weiss G.Ride on the ferrous wheel—The cycle of iron in macrophages in health and disease. Immunobiology, 2014. http//

Most read articles by the same author(s)